• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    11/14/24 5:47:15 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COGT alert in real time by email
    SC 13G/A 1 tm2428137d5_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)*

     

    Cogent Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    19240Q201

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

      x Rule 13d-1(c)

      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 19240Q201 Page 2 of 16

     

    1.

    Name of Reporting Persons

    Venrock Healthcare Capital Partners II, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    PN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 3 of 16

     

    1.

    Name of Reporting Persons

    VHCP Co-Investment Holdings II, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer's Common Stock outstanding as of August 2, 2024, as reported in the Issuer's Quarterly Report on Form 10 - Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 4 of 16

     

    1.

    Name of reporting persons

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    PN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 5 of 16

     

    1.

    Name of reporting persons

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 6 of 16

     

    1.

    Name of reporting persons

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    PN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 7 of 16

     

    1.

    Name of reporting persons

    VHCP Management II, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 8 of 16

     

    1.

    Name of reporting persons

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 9 of 16

     

    1.

    Name of reporting persons

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 10 of 16

     

    1.

    Name of Reporting Persons

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    IN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 11 of 16

     

    1.

    Name of Reporting Persons

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    11,516,6672

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    11,516,6672

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    11,516,6672

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

    IN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

    2Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

    3This percentage is calculated based upon (i) 109,450,463 shares of the Issuer’s Common Stock outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 plus (ii) 5,832,500 shares of common stock issuable upon conversion of Series A stock held by the Reporting Persons.

     

     

     

     

    CUSIP No. 19240Q201 Page 12 of 16

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP-II”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP-II Co-Invest”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP-III”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP-III Co-Invest”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP-EG”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCPM-II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCPM-III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCPM-EG” and collectively with VHCP II, VHCP-II Co-Invest, VHCP-III, VHCP-III Co-Invest, VHCP-EG, VHCPM-II and VHCPM-III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Cogent Biosciences, Inc.

     

    Item 1.

     

      (a) Name of Issuer

     

    Cogent Biosciences, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

    275 Wyman Street, 3rd Floor

    Waltham, MA 02451

     

    Item 2.

     

      (a) Name of Person Filing

     

    Venrock Healthcare Capital Partners II, L.P.

    VHCP Co-Investment Holdings II, LLC

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management II, LLC

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c) Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.001 per share

     

      (e) CUSIP Number

     

    19240Q201

     

     

     

     

    CUSIP No. 19240Q201 Page 13 of 16

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned as of September 30, 2024:

     

    Venrock Healthcare Capital Partners II, L.P.   11,516,667 (1)
    VHCP Co-Investment Holdings II, LLC   11,516,667 (1)
    Venrock Healthcare Capital Partners III, L.P.   11,516,667 (1)
    VHCP Co-Investment Holdings III, LLC   11,516,667 (1)
    Venrock Healthcare Capital Partners EG, L.P.   11,516,667 (1)
    VHCP Management II, LLC   11,516,667 (1)
    VHCP Management III, LLC   11,516,667 (1)
    VHCP Management EG, LLC   11,516,667 (1)
    Nimish Shah   11,516,667 (1)
    Bong Koh   11,516,667 (1)

     

      (b) Percent of Class as of September 30, 2024:

     

    Venrock Healthcare Capital Partners II, L.P.   9.99 %
    VHCP Co-Investment Holdings II, LLC   9.99 %
    Venrock Healthcare Capital Partners III, L.P.   9.99 %
    VHCP Co-Investment Holdings III, LLC   9.99 %
    Venrock Healthcare Capital Partners EG, L.P.   9.99 %
    VHCP Management II, LLC   9.99 %
    VHCP Management III, LLC   9.99 %
    VHCP Management EG, LLC   9.99 %
    Nimish Shah   9.99 %
    Bong Koh   9.99 %

     

      (c) Number of shares as to which the person has, as of September 30, 2024:

     

      (i) Sole power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   0  
    VHCP Co-Investment Holdings II, LLC   0  
    Venrock Healthcare Capital Partners III, L.P.   0  
    VHCP Co-Investment Holdings III, LLC   0  
    Venrock Healthcare Capital Partners EG, L.P.   0  
    VHCP Management II, LLC   0  
    VHCP Management III, LLC   0  
    VHCP Management EG, LLC   0  
    Nimish Shah   0  
    Bong Koh   0  

     

     

     

     

      (ii) Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   11,516,667 (1)
    VHCP Co-Investment Holdings II, LLC   11,516,667 (1)
    Venrock Healthcare Capital Partners III, L.P.   11,516,667 (1)
    VHCP Co-Investment Holdings III, LLC   11,516,667 (1)
    Venrock Healthcare Capital Partners EG, L.P.   11,516,667 (1)
    VHCP Management II, LLC   11,516,667 (1)
    VHCP Management III, LLC   11,516,667 (1)
    VHCP Management EG, LLC   11,516,667 (1)
    Nimish Shah   11,516,667 (1)
    Bong Koh   11,516,667 (1)

     

      (iii) Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   0  
    VHCP Co-Investment Holdings II, LLC   0  
    Venrock Healthcare Capital Partners III, L.P.   0  
    VHCP Co-Investment Holdings III, LLC   0  
    Venrock Healthcare Capital Partners EG, L.P.   0  
    VHCP Management II, LLC   0  
    VHCP Management III, LLC   0  
    VHCP Management EG, LLC   0  
    Nimish Shah   0  
    Bong Koh   0  

     

      (iv) Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   11,516,667 (1)
    VHCP Co-Investment Holdings II, LLC   11,516,667 (1)
    Venrock Healthcare Capital Partners III, L.P.   11,516,667 (1)
    VHCP Co-Investment Holdings III, LLC   11,516,667 (1)
    Venrock Healthcare Capital Partners EG, L.P.   11,516,667 (1)
    VHCP Management II, LLC   11,516,667 (1)
    VHCP Management III, LLC   11,516,667 (1)
    VHCP Management EG, LLC   11,516,667 (1)
    Nimish Shah   11,516,667 (1)
    Bong Koh   11,516,667 (1)

     

    1Consists of (i) 788,162 shares of common stock and 1,542,716 shares of common stock issuable upon the conversion of Series A non-voting convertible preferred stock (“Series A stock”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 319,465 shares of common stock and 623,204 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings II, LLC, (iii) 2,373,381 shares of common stock and 3,333,950 shares of common stock issuable upon the conversion of Series A stock held by Venrock Healthcare Capital Partners III, L.P., (iv) 237,682 shares of common stock and 332,630 shares of common stock issuable upon the conversion of Series A stock held by VHCP Co-Investment Holdings III, LLC., and (v) 1,965,477 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon the voluntary conversion of the Reporting Persons’ Series A stock pursuant to the Certificate of Designation for the Series A stock as a result of the blocker provision of the Certificate of Designation described in the following sentence. The Certificate of Designation provides that the holder of Series A stock will not have a right to convert, subject to certain exceptions, the Series A stock for common stock if, as a result of such conversion, the holder, together with its affiliates and other attribution parties, would exceed a beneficial ownership limitation to be set at the discretion of the holder between 4.9% and 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock being converted. The Reporting Persons have set the beneficial ownership limitation at 9.99%.

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 19240Q201 Page 15 of 16

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners II, L.P.  Venrock Healthcare Capital Partners III, L.P.
        
    By: VHCP Management II, LLC  By: VHCP Management III, LLC
    Its: General Partner  Its: General Partner
        
    By: /s/ Sherman G. Souther  By: /s/ Sherman G. Souther
      Name: Sherman G. Souther    Name: Sherman G. Souther
      Its: Authorized Signatory    Its: Authorized Signatory

     

    VHCP Co-Investment Holdings II, LLC   Venrock Healthcare Capital Partners III, L.P.
         
    By: VHCP Management II, LLC   By: VHCP Management II, LLC
    Its: Manager   Its: Manager
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    Venrock Healthcare Capital Partners EG, L.P.    
         
    By: VHCP Management EG, LLC      
    Its: General Partner      
         
    By: /s/ Sherman G. Souther      
      Name: Sherman G. Souther        
      Its: Authorized Signatory        

     

    VHCP Management II, LLC   VHCP Management III, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

    VHCP Management EG, LLC    
         
    By: /s/ Sherman G. Souther      
      Name: Sherman G. Souther        
      Its: Authorized Signatory        

     

    Nimish Shah   Bong Koh
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Sherman G. Souther, as attorney-in-fact     Sherman G. Souther, as attorney-in-fact

     

     

     

     

    CUSIP No. 19240Q201 Page 16 of 16

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on February 14, 2024)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed on July 20, 2020)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on July 20, 2020)

     

     

     

    Get the next $COGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COGT

    DatePrice TargetRatingAnalyst
    11/10/2025$40.00Hold → Buy
    Stifel
    11/10/2025$38.00Neutral → Outperform
    Wedbush
    10/16/2025$16.00Hold
    Stifel
    9/3/2025$30.00Strong Buy
    Raymond James
    3/7/2025$17.00Sector Outperform
    Scotiabank
    12/11/2024Buy → Hold
    Needham
    2/26/2024$14.00 → $8.00Outperform → Neutral
    Robert W. Baird
    2/8/2024$11.00Buy
    Citigroup
    More analyst ratings

    $COGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cogent Biosciences upgraded by Stifel with a new price target

    Stifel upgraded Cogent Biosciences from Hold to Buy and set a new price target of $40.00

    11/10/25 11:01:45 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences upgraded by Wedbush with a new price target

    Wedbush upgraded Cogent Biosciences from Neutral to Outperform and set a new price target of $38.00

    11/10/25 10:13:55 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Cogent Biosciences with a new price target

    Stifel initiated coverage of Cogent Biosciences with a rating of Hold and set a new price target of $16.00

    10/16/25 8:24:32 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ferrante Karen Jean

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    10/3/25 4:16:22 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fairmount Funds Management Llc bought $24,999,993 worth of shares (2,777,777 units at $9.00) (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    7/14/25 4:30:37 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ferrante Karen Jean

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    7/2/25 4:15:43 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    SEC Filings

    View All

    SEC Form 8-K filed by Cogent Biosciences Inc.

    8-K - Cogent Biosciences, Inc. (0001622229) (Filer)

    12/8/25 4:05:52 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Cogent Biosciences, Inc. (0001622229) (Filer)

    11/18/25 4:09:49 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.

    SCHEDULE 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/25 4:16:57 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $24,999,993 worth of shares (2,777,777 units at $9.00) (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    7/14/25 4:30:37 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Pinnow Cole bought $332,412 worth of shares (43,750 units at $7.60), increasing direct ownership by 2,085% to 45,848 units (SEC Form 4)

    4 - Cogent Biosciences, Inc. (0001622229) (Issuer)

    1/15/25 7:00:04 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

    -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates – -- Bezuclastinib was very well tolerated with only 14.8% of patients requiring dose reduction and no patients requiring discontinuation due to treatment related adverse events -- -- APEX NDA submission expected in 1H 2026 – -- Cogent to host investor conference call and webcast today at 8:00 a.m. ET -- WALTHAM, Mass. and BOULDER, Colo.,

    12/8/25 7:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

    -- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients -- -- New 48-week data demonstrate a clear, continued deepening of symptomatic improvement over time -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use --  -- Granted Breakthrough Therapy Designation for bezuclastinib in October 2025; New Drug Applic

    12/6/25 9:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

    WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:30 a.m. GMT (6:30 a.m. ET). A live webcast will be available on the Investors & Media page of Cogent's website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Cogent Biosciences, Inc.Cogent Biosciences is a biotechnology company focu

    11/14/25 8:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Leadership Updates

    Live Leadership Updates

    View All

    Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

    WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients

    5/23/24 5:05:00 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

    WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of Clinical Development. "We are pleased to welcome Dr. Easton to Cogent as we continue to develop bezuclastinib in Systemic Mastocytosis and GIST," said Andrew Robbins, the company's President and Chief Executive Officer. "Dr. Easton is an accomplished physician-scientist who brings a wealth of experience in both early and late-stage clinical development across multiple therapeutic areas. Her backgrou

    11/28/22 4:15:00 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer

    CAMBRIDGE, Mass. and BOULDER, Colo., May 3, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Evan Kearns as Chief Legal Officer. In his new role, Mr. Kearns will oversee all corporate legal operations for Cogent Biosciences. "I am excited to welcome Evan to the Cogent team as our Chief Legal Officer," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "Evan's expert counsel and proven leadership in ad

    5/3/21 7:00:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Financials

    Live finance-specific insights

    View All

    Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

    -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates – -- Bezuclastinib was very well tolerated with only 14.8% of patients requiring dose reduction and no patients requiring discontinuation due to treatment related adverse events -- -- APEX NDA submission expected in 1H 2026 – -- Cogent to host investor conference call and webcast today at 8:00 a.m. ET -- WALTHAM, Mass. and BOULDER, Colo.,

    12/8/25 7:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

    -- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients -- -- New 48-week data demonstrate a clear, continued deepening of symptomatic improvement over time -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use --  -- Granted Breakthrough Therapy Designation for bezuclastinib in October 2025; New Drug Applic

    12/6/25 9:30:00 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

    -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo -- -- Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use in this patient population -- -

    7/7/25 7:06:05 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 7:59:55 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 5:47:15 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cogent Biosciences Inc.

    SC 13G/A - Cogent Biosciences, Inc. (0001622229) (Subject)

    11/14/24 4:05:10 PM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care